This study is being conducted to compare the effectiveness and safety of a new drug called rinatabart sesutecan against other treatments chosen by a doctor. The research focuses on individuals with endometrial cancer, which is a type of cancer that starts in the lining of the uterus. This study specifically involves patients whose cancer is advanced, has returned after previous treatment, or has spread to other parts of the body. The participants in this trial have previously received platinum-based chemotherapy and PD(L)-1 therapy, which are types of treatments used to kill cancer cells or help the immune system fight the disease.

In this study, participants will receive either rinatabart sesutecan or a treatment selected by their doctor, which may include medications such as doxorubicin or paclitaxel. These medications are administered through an IV infusion, a method where medicine is delivered directly into a vein through a small tube. The study aims to determine if the new drug works better than the standard options currently available for this condition.

During the course of the study, participants will undergo regular monitoring to track how the cancer responds to the medication and to observe any side effects. The researchers will look at how long the cancer remains stable without growing and the overall survival of the participants. This process involves continuous observation over several years to collect data on how the treatments affect the health and well-being of the individuals involved.